HAEMONETICS CORP

Company Overview

Haemonetics is a global medical-technology company organized into three reporting segments—Plasma, Blood Center and Hospital—that design, manufacture and sell capital equipment, consumables and software for plasma collection centers, blood banks and hospitals. In FY2025 the company generated $1.361 billion of revenue (Hospital ~42%, Plasma ~39%, Blood Center ~19%), with Hospital delivering strong growth (23.7%) while Plasma and Blood Center declined due in part to a major CSL Plasma customer transition and the January 2025 divestiture of the Whole Blood product line. The firm sells in ~95 countries through a mix of direct sales and distributors, operates in-house consumables manufacturing (North America, Malaysia) plus contract production, and focuses R&D on Plasma and Hospital portfolios with recent FDA and CE milestones. Key operational risks include regulatory approvals (FDA/CE/MDR), supply‑chain concentration for plastics/sole‑source components, customer concentration (top 10 ≈42% of revenues) and near‑term financing and integration considerations tied to recent acquisitions and convertible note maturities.

Executive Compensation Practices

Given Haemonetics’ mix of recurring consumables sales and capital equipment adoption cycles, executive pay is likely tied to a mix of near‑term financial metrics (revenue growth by segment—notably Hospital and Plasma—gross margin and operating income) and longer‑term metrics (EPS/adjusted EPS, operating cash flow, integration milestones from acquisitions and total shareholder return). Regulatory and product milestones (FDA clearances, CE markings, new assay cartridges or system approvals) are material to commercial adoption and commonly form the basis for performance‑based equity or cash bonuses in medical‑device companies. The company’s recent capital moves—issuance and refinancing of convertible notes, term loan and a $500M share‑repurchase authorization—also create incentives to manage leverage and free cash flow, so compensation plans may include leverage or net‑debt-related goals and retention awards tied to successful refinancing or realization of synergies from M&A. Typical sector practice (and likely at Haemonetics) combines base salary, annual cash incentives, and long‑term equity (RSUs/PSUs or options) with multi‑year vesting and performance conditions; contingent consideration remeasurements from acquisitions can also affect reported performance and bonus funding.

Insider Trading Considerations

Insider trading activity at Haemonetics will likely cluster around clearly material operational and corporate events: quarterly earnings, FDA/CE regulatory clearances or clinical/assay milestones, major customer transitions (e.g., CSL Plasma), acquisition announcements or integration milestones (OpSens, Attune), and financing events such as the March 2026 $300M convertible note maturity or any refinancing. The healthcare/device regulatory environment and anti‑kickback/compliance risks mean executives must be cautious about trading on material nonpublic information related to contracts, approvals or supply issues; you should expect use of blackout periods and 10b5‑1 trading plans and prompt Section 16/Form 4 disclosures by insiders. Because management has an active buyback program and contingent consideration adjustments that materially affect earnings, insider purchases or sales around repurchase program starts/stops or remeasurement outcomes can be particularly informative to investors monitoring confidence in the outlook.